Mavacamten in Hypertrophic Cardiomyopathy: Unraveling Therapeutic Potential and Clinical Implications in Advancing Cardiovascular Medicine

Abstract

Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by myocardial hypertrophy, often leading to various cardiovascular symptoms and complications. While traditional management approaches focus on symptom control, the emergence of mavacamten, a novel cardiac myosin inhibitor, has revolutionized treatment strategies. Mavacamten selectively targets hypercontractility in sarcomeres, addressing the underlying pathophysiology of HCM. This manuscript provides a comprehensive overview of the pathophysiology of HCM, the pharmacological and pharmacokinetic profile of mavacamten, preclinical and clinical trial data, adverse events associated with its use, company agreements, and limitations in its clinical application. Clinical trials demonstrate mavacamten's efficacy in reducing left ventricular outflow tract obstruction, improving symptoms, and mitigating adverse cardiac remodeling in patients with HCM. Despite its promising therapeutic potential, mavacamten presents challenges such as contraindications and potential adverse effects, necessitating careful patient selection and monitoring. Overall, mavacamten represents a significant advancement in the treatment landscape for symptomatic HCM, offering a promising avenue for improved patient outcomes.